natgillin/translations-raw huggingface dataset:
It is considered likely that ganciclovir causes temporary or permanent inhibition of spermatogenesis (see sections 4.6, 4.8 and 5.3). 
Verjetno je, da ganciklovir prehodno ali trajno zavre spermatogenezo (glejte poglavja 4.6, 4.8 in 5.3).
As dosage modifications are recommended in patients with renal impairment, serum creatinine or estimated creatinine-clearance levels should be monitored. 
Ker je za bolnike z okvaro ledvic priporočena prilagoditev odmerjanja, jim je treba kontrolirati kreatinin v serumu ali ocenjeno vrednost očistka kreatinina.
Cymevene is used to treat diseases caused by a virus called cytomegalovirus (CMV) in patients who have a weak immune system. 
Zdravilo Cymevene uporabljamo za zdravljenje bolezni, ki jo povzroča virus, imenovan citomegalovirus (CMV), pri bolnikih z oslabljenim imunskim sistemom.
Further phosphorylation occurs by several cellular kinases to produce ganciclovir triphosphate, which is then slowly metabolised intracellularly. 
Nadaljnja fosforilacija poteka z več celičnimi kinazami, tako da nastane ganciklovir-trifosfat, ki se nato počasi presnovi znotraj celice.
This adverse reaction has only been reported in studies in AIDS patients treated with Cymevene for CMV retinitis. 
O tem neželenem učinku so poročali le v študijah pri bolnikih z AIDSom, ki so zdravilo Cymevene prejemali za zdravljenje citomegalovirusnega retinitisa.
Therefore, patients taking probenecid and Cymevene should be closely monitored for ganciclovir toxicity. 
Zato je treba bolnike, ki sočasno dobivajo probenecid in zdravilo Cymevene, skrbno spremljati glede toksičnih učinkov ganciklovirja.
Toxicity may be enhanced when ganciclovir is co-administered with other drugs known to be myelosuppressive or associated with renal impairment (such as dapsone, pentamidine, flucytosine, vincristine, vinblastine, doxorubicin, amphotericin B, mycophenolate mofetil, trimethoprim/sulphamethoxazole, and hydroxyurea) as well as nucleoside analogues (including zidovudine). 
Toksičnost se lahko poveča, če je ganciklovir uporabljen sočasno z drugimi zdravili, za katera je znano, da so mielosupresivna ali so povezana z okvaro ledvic (npr. dapson, pentamidin, flucitozin, vinkristin, vinblastin, doksorubicin, amfotericin B, mofetilmikofenolat, trimetoprim/sulfametoksazol in hidroksisečnina), ter z nukleozidnimi analogi (vključno z zidovudinom).
Therefore, ganciclovir should not be used in pregnant women unless the clinical need for treatment of the woman outweighs the potential teratogenic risk to the foetus. 
Zato se ga ne sme uporabljati pri nosečnicah, razen če klinična potreba po zdravljenju bolnice odtehta možna teratogena tveganja za plod.
The volume of distribution of intravenously administered ganciclovir is correlated to body weight. 
Porazdelitev Volumen porazdelitve intravensko uporabljenega ganciklovirja korelira s telesno maso.
Ganciclovir was mutagenic in mouse lymphoma cells and clastogenic in mammalian cells. 
Ganciklovir je bil mutagen v celicah mišjega limfoma in klastogen v celicah sesalcev.
• hives, dry skin 
• koprivnica, suha koža
Do not use Cymevene if any of the above apply to you. 
Ne uporabljajte zdravila Cymevene, če kaj od naštetega velja za vas.
Dermatitis Night sweats Pruritus 
dermatitis nočno znojenje srbenje
None of the children required a cochlear implant and hearing loss improved in 83% of ears affected by hearing loss at baseline. 
Nobeden od teh otrok ni potreboval kohlearnega vsadka in poslabšanje sluha se je izboljšalo pri 83 %
As the phosphorylation is largely dependent on the viral kinase, phosphorylation of ganciclovir occurs preferentially in virus-infected cells. 
Ker je fosforilacija v veliki meri odvisna od virusne kinaze, poteka fosforilacija ganciklovirja predvsem v celicah, okuženih z virusom.
Other potential drug interactions 
Druga možna medsebojna delovanja z zdravili
• hands or feet feeling weak or numb, which may affect your balance 
• občutek šibkosti ali omrtvičenosti dlani in stopal; to vam lahko poslabša ravnotežje
• feeling agitated or nervous 
• vznemirjenost ali živčnost
The pharmacokinetic properties of ganciclovir have been evaluated in HIV- and CMV-seropositive patients, patients with AIDS and CMV retinitis, and in solid organ transplant patients. 
Farmakokinetične lastnosti ganciklovirja so ocenili pri HIV- in CMV-seropozitivnih bolnikih, bolnikih z AIDSom in citomegalovirusnim retinitisom ter prejemnikih presajenih solidnih organov.
Powder: Does not require any special storage conditions. 
Prašek: Za shranjevanje zdravila niso potrebna posebna navodila.
This is because Cymevene may harm the unborn baby. 
Zdravilo Cymevene namreč lahko škoduje nerojenemu otroku.
• a skin reaction where the medicine was injected - such as inflammation, pain and swelling. 
• kožna reakcija na mestu, kjer je bilo injicirano zdravilo - na primer vnetje, bolečine in oteklost.
• you are breast-feeding (see Breast-feeding subsection). 
• če dojite (glejte podpoglavje Dojenje).
Ganciclovir is removed by haemodialysis, therefore haemodialysis may be of benefit in reducing drug exposure in patients who receive an overdose of ganciclovir (see section 5.2). 
Ganciklovir se odstranjuje s hemodializo, zato lahko hemodializa koristi za zmanjšanje izpostavljenosti zdravilu pri bolnikih, ki dobijo prevelik odmerek ganciklovirja (glejte poglavje 5.2).
The pharmacokinetics of intravenous ganciclovir were investigated in neonates aged 2−49 days following doses of 4 mg/kg (N = 14) and 6 mg/kg (N = 13). 
Pediatrična populacija Farmakokinetiko intravenskega ganciklovirja so raziskali pri novorojenčkih, starih od 2 do 49 dni, po uporabi odmerkov 4 mg/kg (n = 14) in 6 mg/kg (n = 13).
Patients with renal impairment have an increased elimination half-life and, depending on renal function, it ranges from about 6 to 17 hours (see section 4.2 for dose modifications required in patients with renal impairment). 
Bolniki z okvaro ledvic imajo podaljšan eliminacijski razpolovni čas, ki - odvisno od delovanja ledvic - sega od približno 6 do 17 ur (za prilagoditev odmerka, potrebno pri bolnikih z okvaro ledvic, glejte poglavje 4.2).
Other adverse drugs reactions are presented in the table below. 
Drugi neželeni učinki zdravila so prikazani v spodnji preglednici.
For patients with severe leucopenia, neutropenia, anaemia and/or thrombocytopenia it is recommended to consider the use of treatment with haematopoietic growth factors and/or the interruption of ganciclovir therapy (see sections 4.2 and 4.8). 
Pri bolnikih s hudo levkopenijo, nevtropenijo, anemijo in/ali trombocitopenijo je priporočljivo razmisliti o zdravljenju s hematopoetskimi rastnimi faktorji in/ali o prekinitvi zdravljenja z ganciklovirjem (glejte poglavji 4.2 in 4.8).
LIST OF EXCIPIENTS This medicinal product contains sodium. 
SEZNAM POMOŽNIH SNOVI To zdravilo vsebuje natrij.
• imipenem/cilastatin - used for bacterial infections, 
• imipenem/cilastatin - uporabljata se za zdravljenje bakterijskih okužb,
• The active substance is ganciclovir. 
• Zdravilna učinkovina je ganciklovir.
Cymevene and associated names (see Annex I) 500 mg powder for concentrate for solution for infusion 
Cymevene in povezana imena (glejte Prilogo I) 500 mg prašek za koncentrat za raztopino za infundiranje
Prevention of CMV disease in adults and adolescents from 12 years of age with normal renal function using prophylaxis or pre-emptive therapy 
Preprečevanje citomegalovirusne bolezni pri odraslih in mladostnikih, starejših od 12 let, z normalnim delovanjem ledvic, z uporabo profilakse ali preventivnega zdravljenja
Mean Cmax was 5.5 ± 6 µg/mL at 4 mg/kg and 7.0 ± 1.6 µg/mL at 6 mg/kg. 
Povprečna Cmax je bila 5,5 ± 6 µg/ml ob odmerku 4 mg/kg in 7,0 ± 1,6 µg/ml ob odmerku 6 mg/kg.
Ganciclovir was effective with a toxicity profile similar to that seen in adults. 
Ganciklovir je bil učinkovit in toksične značilnosti so bile podobne kot pri odraslih.
After dilution in infusion solutions (sodium chloride 0.9%, dextrose 5%, Ringer's or lactated Ringer's solution for injection) : 
Po razredčenju z raztopinami za infundiranje (0,9-% natrijevim kloridom, 5-% dekstrozo, Ringerjevo ali Ringer-laktatno raztopino za injekcije):
Other medicines and Cymevene Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. 
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
Therapeutic guidelines should be consulted. 
Upoštevati je treba smernice za zdravljenje.
Decreased appetite Anorexia 
zmanjšan apetit anoreksija zmanjšanje telesne mase
Exposure as measured by mean AUC0−∞ on Days 1 and 14 were 19.4 ± 7.1 and 24.1 ± 14.6 µg.h/mL, respectively, and the corresponding Cmax values were 7.59 ± 3.21 µg/mL (Day 1) and 8.31 ± 4.9 µg/mL (Day 14). 
Izpostavljenost, merjena s povprečno AUC0−∞ 1. oziroma 14. dan, je bila 19,4 ± 7,1 in 24,1 ± 14,6 µg.h/ml, ustrezni vrednosti Cmax pa sta bili 7,59 ± 3,21 µg/ml (1. dan) in 8,31 ± 4,9 µg/ml (14. dan).
During the course of the study, 29/46 ganciclovir-treated patients had neutropenia, compared with 9/43 control patients (p < 0.1). 
Med študijo se je nevtropenija pojavila pri 29 od 46 bolnikov, zdravljenih z ganciklovirjem, in pri 9 od 43 kontrolnih bolnikov (p < 0,1).
See Serious side effects at the top of section 4 for more information. 
Za več informacij glejte Resni neželeni učinki na začetku poglavja 4.
This has been shown to occur in HSV- and HCMV-infected cells, with half-lives of 18 and 6−24 hours, respectively, after removal of extracellular ganciclovir. 
Ugotovljeno je, da to poteka v celicah, okuženih s HSV oz. HCMV, z razpolovnim časom 18 oz. od 6 do 24 ur po odstranitvi zunajceličnega ganciklovirja.
For patients with renal impairment, the dose of ganciclovir should be modified according to creatinine clearance as shown in the table below (see sections 4.4 and 5.2). 
Bolnikom z okvaro ledvic je treba odmerek ganciklovirja prilagoditi glede na očistek kreatinina, kot prikazuje spodnja preglednica (glejte poglavji 4.4 in 5.2).
Patients treated with ganciclovir and didanosine, medicines known to be myelosuppressive or affecting renal function, should be closely monitored for signs of added toxicity (see section 4.5). 
Bolnike, ki dobivajo ganciklovir z didanozinom, znanimi mielosupresivnimi zdravili ali z zdravili, ki vplivajo na delovanje ledvic, je treba skrbno spremljati glede znakov dodatne toksičnosti (glejte poglavje 4.5).
Available in packs of 1 vial or 5 vials. 
Zdravilo je na voljo v pakiranjih z 1 ali 5 vialami.
Therefore, women of child bearing potential must be advised to use effective contraception during treatment and for at least 30 days thereafter. 
Ženskam v rodni dobi je treba naročiti, da morajo med zdravljenjem in vsaj še 30 dni po zdravljenju porabljati učinkovito kontracepcijo.
It is used in adults and adolescents 12 years and older. 
Zdravilo je namenjeno uporabi pri odraslih in otrocih, starih 12 let ali več.
Viral resistance to ganciclovir can arise by selection of mutations in the viral kinase gene (UL97) responsible for ganciclovir monophosphorylation and/or the viral polymerase gene (UL54). 
Odpornost virusov proti ganciklovirju se lahko pojavi s selekcijo mutacij v genu virusne kinaze (UL97), odgovorne za monofosforilacijo ganciklovirja, in/ali genu virusne polimeraze (UL54).
SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET 
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA, OZNAČEVANJE IN NAVODILO ZA
Sodium hydroxide (for pH-adjustment) Hydrochloric acid (for pH-adjustment) 
Natrijev hidroksid (za prilagoditev pH)
Severe thrombocytopenia may be associated with potentially life-threatening bleeding. 
Hudo trombocitopenijo lahko spremljajo potencialno smrtno nevarne krvavitve.
Haemodialysis reduces plasma concentrations of ganciclovir by about 50% after intravenous administration during a 4-hour haemodialysis session. 
Hemodializa zniža koncentracijo ganciklovirja v plazmi za približno 50 % po intravenski uporabi med 4-urno hemodializo.
Look out for these while you are taking Cymevene - your doctor may tell you to stop taking Cymevene and you may need urgent medical treatment: 
Med jemanjem zdravila Cymevene bodite pozorni na naslednje - zdravnik vam bo morda naročil, da nehate uporabljati zdravilo Cymevene, in morda boste potrebovali nujno zdravljenje:
The overall incidence of CMV was 16% (15/92 patients). 
Celotna incidenca CMV je bila 16 %
Mutagenicity, teratogenicity, carcinogenicity, fertility, and contraception 
Mutagenost, teratogenost, kancerogenost, plodnost in kontracepcija
Cytochrome P450 isoenzymes play no role in ganciclovir pharmacokinetics. 
Druga protiretrovirusna zdravila Izoencimi citokroma P450 ne igrajo nobene vloge v farmakokinetiki ganciklovirja.
Tell your doctor straight away if you notice any of the following serious side effects - your doctor may tell you to stop taking Cymevene and you may need urgent medical treatment: 
Zdravnika morate nemudoma obvestiti, če opazite katerega od naslednjih resnih neželenih učinkovzdravnik vam lahko naroči, da prenehate jemati zdravilo Cymevene; morda boste potrebovali nujno zdravljenje:
The pharmacokinetic characteristics of ganciclovir were the same after single and multiple (q12h) 5 mg/kg intravenous doses. 
Farmakokinetične značilnosti ganciklovirja so bile po enkratnem in večkratnih (na 12 ur) intravenskih odmerkih 5 mg/kg enake.
• feeling tired, dizzy, weak or generally unwell 
• utrujenost, omotica, šibkost ali splošno slabo počutje
• low blood pressure, which may make you feel dizzy or faint 
• nizek krvni tlak, ki lahko povzroči omotico ali omedlevico
In patients treated with ganciclovir the most serious and common adverse drug reactions are haematological reactions and include neutropenia, anaemia and thrombocytopenia. 
Pri bolnikih, zdravljenih z ganciklovirjem, so najresnejši in najpogostejši neželeni učinki hematološke reakcije, ki vključujejo nevtropenijo, anemijo in trombocitopenijo.
Plasma protein binding was 1%−2% over ganciclovir concentrations of 0.5 and 51 µg/mL. 
Vezava na beljakovine v plazmi je bila ob koncentracijah ganciklovirja od 0,5 do 51 µg/ml od 1 do 2 %.
{(Invented) name and associated names (see Annex I) strength pharmaceutical form} [See Annex I - To be completed nationally] 
{(Izmišljeno) ime in povezana imena (glejte Prilogo I) jakost farmacevtska oblika} [Glejte Prilogo I - Izpolni država članica]
Ganciclovir must be administered by intravenous infusion over 1 hour at a concentration not exceeding 10 mg/mL. 
Ganciklovir je treba dajati v intravenski infuziji v teku ene ure, koncentracija pa ne sme preseči
Thrombocytopenia Leucopenia Pancytopenia 
trombocitopenija levkopenija pancitopenija
• bacterial skin infection - signs include red, painful or swollen skin 
• bakterijska okužba kože - med znaki so rdeča, boleča ali otekla koža
• you have kidney problems - your doctor will need to give you a lower dose and check your blood cell counts more often during treatment 
• če imate težave z ledvicami - zdravnik vam bo moral dati manjši odmerek in med zdravljenjem pogosteje kontrolirati krvno sliko.
• feeling depressed, anxious, confused or having abnormal thoughts 
• občutek potrtosti, tesnobnost, zmedenost ali nenormalne misli
Mean values for the steady state volume of distribution (0.7 L/kg) and systemic clearance (3.15 ± 0.47 mL/min/kg at 4 mg/kg and 3.55 ± 0.35 mL/min/kg at 6 mg/kg) were comparable to those observed in adults with normal renal function. 
Povprečne vrednosti volumna porazdelitve v stanju dinamičnega ravnovesja (0,7 l/kg) in sistemskega očistka (3,15 ± 0,47 ml/min/kg ob 4 mg/kg in 3,55 ± 0,35 ml/min/kg ob 6 mg/kg) so bile podobne kot pri odraslih z normalnim delovanjem ledvic.
The vial should be gently swirled in order to ensure complete wetting of the product. 
Vialo je treba previdno sukati, da je zagotovljeno popolno omočenje zdravila.
• muscle pain or spasms 
• mišične bolečine ali krči (spazmi)
Neutropenia was the only severe adverse drug reaction observed during the study and although none of the children required treatment cessation, 4 required granulocyte colony-stimulating factor (G-CSF) treatment to maintain absolute neutrophil counts > 400 cells/mm3. 
Pri nobenem otroku sicer ni bilo treba prenehati zdravljenja, a 4 so potrebovali zdravljenje z granulocitne kolonije stimulirajočim faktorjem (G-CSF) za ohranitev absolutnega števila nevtrofilcev > 400 celic/mm3.
During intermittent haemodialysis, estimates for the clearance of ganciclovir ranged from 42−92 mL/min, resulting in intra-dialytic half-lives of 3.3−4.5 hours. 
Med intermitentno hemodializo so ocene očistka ganciklovirja segale od 42−92 ml/min, tako da je bil intradializni razpolovni čas 3,3−4,5 ure.
Since Cymevene is considered a potential teratogen and carcinogen in humans, caution should be observed in its handling. 
Ker velja zdravilo Cymevene pri človeku za potencialno teratogeno in kancerogeno, je pri ravnanju z njim potrebna previdnost.
Cross-hypersensitivity 
Navzkrižna preobčutljivost
- Intravenous ganciclovir 5 mg/kg daily for 6 weeks followed by oral valganciclovir 17 mg/kg twice daily for 6 weeks then daily until 1 year of age, or - Oral valganciclovir 17 mg/kg twice daily for 12 weeks then daily for 9 months. 
- intravenski ganciklovir 5 mg/kg na dan 6 tednov, nato peroralni valganciklovir 17 mg/kg dvakrat na dan 6 tednov in potem enkrat na dan do 1 leta starosti, ali - peroralni valganciklovir 17 mg/kg dvakrat na dan 12 tednov, nato enkrat na dan 9 mesecev.
If you are planning to have a baby, talk to your doctor or pharmacist before using Cymevene. 
Če načrtujete, da bi imeli otroka, se posvetujte z zdravnikom ali farmacevtom, preden začnete uporabljati zdravilo Cymevene.
This medicinal product contains 2 mmol (43mg) sodium per 500 mg dose. 
To zdravilo vsebuje 2 mmola (43 mg) natrija na 500-mg odmerek.
Ganciclovir should therefore be considered a potential teratogen and carcinogen in humans with the potential to cause birth defects and cancers. 
Zato je treba ganciklovir pri človeku obravnavati kot potencialno teratogeno in kancerogeno snov, ki lahko povzroči prirojene hibe in raka.
Refer to treatment guidelines. 
Glejte smernice za zdravljenje.
Treatment of CMV disease in adults and adolescents from 12 years of age with normal renal function 
Zdravljenje citomegalovirusne bolezni pri odraslih in mladostnikih, starejših od 12 let, z normalnim delovanjem ledvic
• serious kidney problems shown in tests 
• resne težave z ledvicami, ki se pokažejo na preiskavah
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: {DD month YYYY} Date of latest renewal: {DD month YYYY} 
Datum prve odobritve: {DD. mesec LLLL}
The flip-off cap should be removed to expose the central portions of the rubber stopper. 
Snemno zaporko je treba odstraniti, da se izpostavi osrednji del gumijastega zamaška.
• liver and kidney problems shown in tests 
• težave z jetri in ledvicami, ki se pokažejo na preiskavah
• trimethoprim, trimethoprim/sulfamethoxazole, dapsone - used for bacterial infections, 
• trimetoprim, trimetoprim/sulfametoksazol, dapson - uporabljajo se za zdravljenje bakterijskih okužb,
• changes in blood cell counts. 
• spremembe krvne slike.
Due to the similarity of the chemical structure of ganciclovir and that of aciclovir and penciclovir, a cross-hypersensitivity reaction between these drugs is possible. 
Kemijska zgradba ganciklovirja je podobna kemijski zgradbi aciklovirja in penciklovirja, zato je med temi zdravili možna navzkrižna preobčutljivost.
Twelve subjects (9.8%) developed CMV disease (8 high-risk vs. 4 routine-risk, p = 0.03). 
Citomegalovirusna bolezen se je razvila pri 12 bolnikih (9,8 %; pri 8 z velikim in 4 z rutinskim tveganjem, p = 0,03).
As a consequence, pharmacokinetic interactions with protease inhibitors and non-nucleoside reverse transcriptase inhibitors are not anticipated. 
Glede na to ni pričakovati farmakokinetičnih medsebojnih delovanj z zaviralci proteaz in zaviralci nenukleozidne reverzne transkriptaze.
treatment of cytomegalovirus (CMV) disease in immunocompromised patients; 
zdravljenje citomegalovirusne (CMV) bolezni pri imunsko oslabelih bolnikih;
Intravenous ganciclovir exhibits linear pharmacokinetics over the range of 1.6−5.0 mg/kg. 
Intravenski ganciklovir ima v območju od 1,6 do 5,0 mg/kg linearno farmakokinetiko.
For instructions on reconstitution of the medicinal product before administration, see section 6.6. 
Za navodila o rekonstituciji zdravila pred dajanjem glejte poglavje 6.6.
After reconstitution with 10 mL of water for injections, each mL provides 50 mg of ganciclovir. 
Po rekonstituciji z 10 ml vode za injekcije en mililiter vsebuje 50 mg ganciklovirja.
Avoid inhalation or direct contact of the powder contained in the vials or direct contact of the reconstituted solution with the skin or mucous membranes. 
Izogibajte se vdihavanju praška ali neposrednemu stiku s praškom v viali in neposrednemu stiku rekonstituirane raztopine s kožo ali sluznicami.
- Prophylaxis: 
- Profilaksa:
Cymevene may affect fertility. 
Zdravilo Cymevene lahko neugodno vpliva na plodnost.
• hydroxyurea - used for a problem called polycythemia, sickle cell disease and cancer, 
• hidroksisečnina - uporablja se za zdravljenje policitemije, bolezni srpastih celic in raka,
Therefore, breastfeeding must be discontinued during treatment with ganciclovir (see section 4.3). 
Zato mora bolnica med zdravljenjem z ganciklovirjem opustiti dojenje (glejte poglavje 4.3).
You may get the following symptoms if you have too much: 
V primeru prevelikega odmerka se vam lahko pojavijo naslednji simptomi:
• changes in blood cell counts 
• spremembe v krvni sliki
• mycophenolate mofetil - used after an organ transplant, 
• mofetilmikofenolat - uporablja se po presaditvah organov,
In animal studies ganciclovir impaired fertility in male and female mice. 
V študijah na živalih je ganciklovir poslabšal plodnost mišjih samcev in samic.
Children and adolescents There is limited information on how safe or effective Cymevene is in children under 12 years. 
Podatkov o varnosti in učinkovitosti zdravila Cymevene pri otrocih, mlajših od 12 let, je malo.
Agitation Psychotic disorder 
agitiranost psihotična motnja
Antiviral Activity 
Protivirusno delovanje
Male patients must be advised to practice barrier contraception during and for at least 90 days following treatment with ganciclovir unless it is certain that the female partner is not at risk of pregnancy (see sections 4.4 and 5.3). 
Moškim je treba naročiti, naj med zdravljenjem in vsaj še 90 dni po zdravljenju z ganciklovirjem uporabljajo pregradno kontracepcijo, razen če je popolnoma gotovo, da partnerka ne more zanositi (glejte poglavji 4.4 in 5.3).
Based on patient weight the appropriate volume should be removed with a syringe from the vial and further diluted into an appropriate infusion solution. 
Priprava končne razredčene raztopine za infundiranje Glede na bolnikovo telesno maso je treba z brizgo izvleči ustrezno količino iz viale in dodatno razredčiti za ustrezno raztopino za infundiranje.
The possibility of viral resistance should be considered in patients who repeatedly achieve a poor clinical response or experience continuous viral excretion during treatment. 
Pri bolnikih, ki ponavljaje dosegajo slab kliničen odziv ali se jim med zdravljenjem stalno izloča virus,
The total plasma clearance of ganciclovir is linearly correlated with creatinine clearance. 
Celotni plazemski očistek ganciklovirja linearno korelira z očistkom kreatinina.
Mean Ganciclovir Plasma half-life (hours) 
Povprečni plazemski razpolovni čas ganciklovirja (ure)
Oral ganciclovir is no longer available but adverse reactions reported with its use can also be expected to occur in patients receiving intravenous ganciclovir. 
Peroralnega ganciklovirja ni več na voljo, vendar je pri bolnikih, ki prejemajo intravenski ganciklovir, mogoče pričakovati tudi neželene učinke, zabeležene med peroralno uporabo.
Cymevene can cause some serious side effects that you need to tell your doctor about straight away. 
Bodite pozorni na neželene učinke Zdravilo Cymevene lahko povzroči nekatere resne neželene učinke, o katerih morate nemudoma obvestiti zdravnika.
How to use Cymevene 
Kako uporabljati zdravilo Cymevene